Recombinant Human Laminin alpha 4 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Laminin alpha 4 Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of HT1080 human fibrosarcoma cells. The ED₅₀ for this effect is 0.7-2.8 μg/mL.
  Optimal dilutions should be determined by each laboratory for each application.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Laminin alpha 4 protein
  Gln826-Ala1816, with a C-terminal 6-His tag
• Accession #: EAW48267
• N-terminal Sequence: Gln826 predicted, sequencing might be blocked, no result obtained
• Structure / Form: Monomer
• Protein/Peptide Type: Recombinant Proteins
• Gene: LAMA4
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 111 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 110-120 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Laminin alpha 4 Protein, CF

• DKFZp686D23145
• LAMA3LAMA4*-1
• LAMA4
• laminin alpha 4 chain
• Laminin alpha 4
• laminin subunit alpha-4
• laminin, alpha 4
• Laminin-14 subunit alpha
• Laminin-8 subunit alpha
• Laminin-9 subunit alpha

Background

The alpha 4 chain of laminin (LAMA4) is a secreted ~210 kDa glycoprotein that contributes to the formation of LN411 (laminin-8, subunits alpha 4 beta 1 gamma 1), LN421 (laminin-9, subunits alpha 4 beta 2 gamma 1), and LN423 (laminin-14, subunits alpha 4 beta 2 gamma 3) (1-4). Laminin alpha ,  beta  and  gamma  subunits interact via alpha -helical domains to create cruciform, disulfide-linked, coiled-coil laminin heterotrimers (1, 2). LAMA4 is mainly expressed in mesodermal tissues, and is produced by endothelium, cardiac and skeletal muscle fibers, lung mesenchymal cells, pre-adipocytes, kidney mesangial cells, peripheral nerves and neutrophils (3-8). It is found in the subendothelium in muscle, brain, and bone marrow, and in heart, skin, and the perineurium of peripheral nerves (3-7, 9, 10). The human LAMA4 cDNA encodes 1823 amino acids (aa), including a 24 aa signal sequence and a 1799 aa mature protein that contains three EGF-like repeats (aa 82-240) followed by five coiled-coil regions (aa 320-806) and five globular, laminin G-like (LG) domains (aa 833-1820). Potential isoforms of 1816 aa and 1791 aa are lacking sequences following the EGF-like repeats. A protease-sensitive region between LG3 and LG4 produces a processed ~180 kDa form that is detected in vivo (9, 10). Within the LG region, human and mouse LAMA4 share 91% aa sequence identity. LAMA4 LG domains serve as Ca⁺⁺-mediated receptors for integrins such as alpha v beta 3 and alpha 3 beta 1 (mainly at LG2), fibulin-1 and -2 (multiple LG), and heparan sulfate proteoglycans such as syndecans 2 and 4 (mainly at LG4) (8-12). Deletion of LAMA4 in mice results in misalignment of pre- and post-synaptic membranes at neuromuscular junctions, faulty nerve myelination, chronic kidney disease, deficient neutrophil extravasation, and microvessel instability, which causes cardiomyopathy and circulatory dysfunctions (5-8, 12-14). These results show the importance of LAMA4-containing laminins in normal synapse maturation and blood vessel maturation.

1. Tzu, J. and M.P. Marinkovich (2008) Int. J. Biochem. Cell Biol. 40:199.
2. Durbeej, M. (2010) Cell Tiss. Res. 339:259.
3. Liu, J. et al. (1996) Matrix Biol. 15:433.
4. Iivanainen, A. et al. (1997) J. Biol. Chem. 272:27862.
5. Patton, B.L. et al. (2001) Nat. Neurosci. 4:597.
6. Wallquist, W. et al. (2005) J. Neurosci. 25:3692.
7. Abrass, C.K. et al. (2010) Am. J. Pathol. 176:839.
8. Wondimu, Z. et al. (2004) Blood 104:1859.
9. Matsuura, H. et al. (2004) J. Invest. Dermatol. 122:614.
10. Talts, J.F. et al. (2000) J. Biol. Chem. 275:35192.
11. Gonzalez, A.M. et al. (2002) Proc. Natl. Acad. Sci. USA 99:16075.
12. DeHahn, K.C. et al. (2004) Exp. Cell Res. 294:281.
13. Thyboll, J. et al. (2002) Mol. Cell Biol. 22:1194.
14. Wang, J. et al. (2006) J. Biol. Chem. 281:213.

Publications for Laminin alpha 4 (7340-A4)(6)

Publications using 7340-A4

• Srinivasan, S;Kryza, T;Bock, N;Tse, BWC;Sokolowski, KA;Janaththani, P;Fernando, A;Moya, L;Stephens, C;Dong, Y;Röhl, J;Alinezhad, S;Vela, I;Perry-Keene, JL;Buzacott, K;Nica, R;IMPACT Study, ;Gago-Dominguez, M;PROFILE Study Steering Committee, ;Schleutker, J;Maier, C;Muir, K;Tangen, CM;Gronberg, H;Pashayan, N;Albanes, D;Wolk, A;Stanford, JL;Berndt, SI;Mucci, LA;Koutros, S;Cussenot, O;Sorensen, KD;Grindedal, EM;Travis, RC;Haiman, CA;MacInnis, RJ;Vega, A;Wiklund, F;Neal, DE;Kogevinas, M;Penney, KL;Nordestgaard, BG;Brenner, H;John, EM;Gamulin, M;Claessens, F;Melander, O;Dahlin, A;Stattin, P;Hallmans, G;Häggström, C;Johansson, R;Thysell, E;Rönn, AC;Li, W;Brown, N;Dimeski, G;Shepherd, B;Dadaev, T;Brook, MN;Spurdle, AB;Stenman, UH;Koistinen, H;Kote-Jarai, Z;Klein, RJ;Lilja, H;Ecker, RC;Eeles, R;Practical Consortium, ;Australian Prostate Cancer BioResource, ;Clements, J;Batra, J; A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer Nature communications 2024-11-06 [PMID: 39505858] (Bioassay, Human)
• MA Gonzalez P, K Stojkova, MK Vaicik, A Pelowe, A Goddi, A Carmona, B Long, AA Qutub, A Gonzalez, RN Cohen, EM Brey Integrins and extracellular matrix proteins modulate adipocyte thermogenic capacity Scientific Reports, 2021-03-08;11(1):5442. 2021-03-08 [PMID: 33686208] (Bioassay, Mouse)
• B Zheng, J Qu, K Ohuchida, H Feng, SJF Chong, Z Yan, Y Piao, P Liu, N Sheng, D Eguchi, T Ohtsuka, K Mizumoto, Z Liu, S Pervaiz, P Gong, M Nakamura LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer Theranostics, 2020-08-13;10(22):10274-10289. 2020-08-13 [PMID: 32929348] (Bioassay, Human)
• M Nakamura, S Shiozawa, D Tsuboi, M Amano, H Watanabe, S Maeda, T Kimura, S Yoshimatsu, F Kisa, CM Karch, T Miyasaka, A Takashima, N Sahara, SI Hisanaga, T Ikeuchi, K Kaibuchi, H Okano Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs Stem Cell Reports, 2019-09-19;13(4):684-699. 2019-09-19 [PMID: 31543469] (Cell Culture, Human)
• ME Burgett, JD Lathia, P Roth, AS Nowacki, DS Galileo, E Pugacheva, P Huang, A Vasanji, M Li, T Byzova, T Mikkelsen, S Bao, JN Rich, M Weller, CL Gladson Direct contact with perivascular tumor cells enhances integrin �v?3 signaling and migration of endothelial cells Oncotarget, 2016-07-12;7(28):43852-43867. 2016-07-12 [PMID: 27270311] (Bioassay, Human)
• Ishikawa T, Wondimu Z, Oikawa Y, Ingerpuu S, Virtanen I, Patarroyo M Monoclonal antibodies to human laminin alpha4 chain globular domain inhibit tumor cell adhesion and migration on laminins 411 and 421, and binding of alpha6beta1 integrin and MCAM to alpha4-laminins. Matrix Biol, 2014-03-27;36(0):5-14. 2014-03-27 [PMID: 24681327] (Bioassay, Enzyme Assay, In Vivo, Human, Mouse)

Bioinformatics

• Gene Symbol: LAMA4
• Uniprot:
  • EAW48267()